Clinical Trial Update: Efficacy and Safety Study of GB-0998 for Guillain-Barré Syndrome [Phase 3]

View source ↗

Summary

The Phase 3 trial evaluating GB-0998 for Guillain-Barré syndrome has completed, but the update does not provide efficacy or safety results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Guillain-barré Syndrome

Drugs mentioned

• GB-0998

Snippet

Sponsor: Japan Blood Products Organization | Conditions: Guillain-Barré Syndrome | Phase 3 | Status: COMPLETED